Get startedLog in
    Picture of Deciphera Pharmaceuticals logo

    DCPH — Deciphera Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Deciphera Pharmaceuticals Inc - Launch Of Qinlock® In Germany Underway Transition To Post-Approval Paid Access Program In France Expected In 1H 2022

    Picture of Deciphera Pharmaceuticals logoDeciphera Pharmaceuticals
    10/01/2022 12:23
    Jan 10 (Reuters) - Deciphera Pharmaceuticals Inc  DCPH.O :
    * DECIPHERA PHARMACEUTICALS INC - LAUNCH OF QINLOCK® IN GERMANY UNDERWAY;
TRANSITION TO POST-APPROVAL PAID ACCESS PROGRAM IN FRANCE EXPECTED IN 1H 2022
    * DECIPHERA PHARMACEUTICALS INC - PIVOTAL PHASE 3 MOTION STUDY OF
VIMSELTINIB IN
TGCT PATIENTS UNDERWAY; UPDATED PHASE 1/2 DATA EXPECTED IN 2H 2022
    * DECIPHERA PHARMACEUTICALS INC - PHASE 1 DOSE ESCALATION DATA FOR DCC-3116
EXPECTED IN 2H 2022
    * DECIPHERA PHARMACEUTICALS INC - NEW PAN-RAF RESEARCH PROGRAM DISCLOSED;
DEVELOPMENT CANDIDATE EXPECTED IN 2022

Source text for Eikon:  ID:nBw9cP783a 
Further company coverage:  DCPH.O

    Recent news on Deciphera Pharmaceuticals

    See all news